Spots Global Cancer Trial Database for A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
Official Title: A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
Study ID: NCT03418922
Conditions
Study Description
Brief Summary: The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Eisai Trial Site 1, Kashiwa, Chiba, Japan
Eisai Trial Site 6, Iizuka, Fukuoka, Japan
Eisai Trial Site 3, Kawasaki, Kanagawa, Japan
Eisai Trial Site 4, Osakasayama, Osaka, Japan
Eisai Trial Site 2, Chuo-ku, Tokyo, Japan
Eisai Trial Site 5, Chiba, , Japan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
